Most cases of pancreatic cancer are diagnosed at an advanced stage, which contributes to the poor prognosis typically associated with the disease. Additionally, late-stage treatment and the associated poor outcomes result in higher costs for the healthcare system.
Molecular testing of tumour tissue has recently been incorporated into the clinical care pathway for metastatic pancreatic cancer (mPDAC). This allows for matching cancer survivors with suitable targeted therapies to enable a more personalized treatment strategy. Despite the increasing recognition of the importance of molecular testing for mPDAC on an international level, this practice has yet to become standard in Canada and is not widely reimbursed.
The CanSURVIVE Research Group will evaluate the cost-effectiveness of implementing genetic profiling of tumour tissue according to the care pathway guidelines. The goal is to provide evidence to support the broader adoption of precision oncology in Canada.
Co-Principal Investigators: Stuart Peacock, BC Cancer, Simon Fraser University; Kelvin Chan, Sunnybrook Odette Cancer Centre, University of Toronto; Winson Cheung, University of Calgary; Scott Gavura, Ontario Health; J Irish; M Tadrous
Principal Investigators: Dr. Renelle Myers, Vancouver General Hospital, University of British Columbia, BC Cancer; Dr. Rayjean Hung, Mount Sinai Hospital, University of Toronto
Principal Investigator: Steven Gallinger, Princess Margaret Cancer Centre, University of Toronto
Co-Principal Investigators: Stuart Peacock, BC Cancer, Simon Fraser University; Francois Bernard, BC Cancer, University of British Columbia; J Valliant; F Prato, W Isaranu-watchai, F Wuest, J Beauregard, K Zukotynski, K Chi, F Saad
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.